Sector News

ThromboGenics Appoints Emmanuele Attout as Independent Non-Executive Director

January 23, 2015
Life sciences
(GLOBE NEWSWIRE) – ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that its Board of Directors has nominated Emmanuèle Attout to be its new Independent non-executive director.  Mrs. Attout will join the Audit Committee of the Company.   
 
Mrs. Attout has been an audit partner at PricewaterhouseCoopers since 1994. She has been in charge of audits of a range of clients including banks, insurance companies, investment funds and assets managers.  She has in recent years been in charge of the audits of listed pharmaceuticals companies and life sciences business out of which she brings substantial relevant experience to the Board and to the Audit Committee.  
 
Dr Staf Van Reet, Chairman of ThromboGenics’ Board of Directors, said: “We are delighted to welcome Emmanuèle to the ThromboGenics’ board as a non-executive director. Her broad business and financial experience, will be extremely valuable to our Board and Audit Committee as we work to execute the standalone strategy we announced in mid-2014.”
   
Commenting on her appointment, Mrs. Attout said: “I am very pleased to be joining the ThromboGenics Board. I have been impressed by the clear strategy that the Company has outlined to build a profitable business focused on providing innovative medicines for the treatment of a number of important vitreo-retinal diseases and I am looking forward to contributing to its successful execution.”
 
Source: ThromboGenics

1 response to “ThromboGenics Appoints Emmanuele Attout as Independent Non-Executive Director

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend